40 results found.

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO).
IPI-145; Ofatumumab

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07.
IPI-145; Ofatumumab

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.
BI 836826

Leukemia Clinical Trial using Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL).
Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), No Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment.

Small Lymphocytic Lymphoma, or CLL (Chronic Lymphocytic Leukemia) Clinical Trial using Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

B-cell Chronic Lymphocytic Leukemia Clinical Trial using Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Lenalidomide (Revlimidr) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second Line Therapy (THE CONTINUUM TRIAL).
Lenalidomide; Placebo

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera.

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL).
Ofatumumab

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.
High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, or Clinical Trial using A6

ngstrom Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia.
A6

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

Advanced Cancers, or Leukemia Clinical Trial using Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

M.D. Anderson Cancer Center - Recruiting 18 years to 80 years.
- Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL).
Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

Leukemia, or Lymphoma Clinical Trial using Rituximab; Lenalidomide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy.
Rituximab; Lenalidomide

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

Hackensack University Medical Center - Recruiting 18 years or older.
- Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance.
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 65 years or older.
- A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (ò 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL).
ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using PCI-32765

Pharmacyclics - Recruiting 65 years or older.
- An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil).
PCI-32765

B-cell Chronic Lymphocytic Leukemia Clinical Trial using B-CLL Vaccine; Lenalidomide

Baylor College of Medicine - Recruiting 18 years to 75 years.
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide.
B-CLL Vaccine; Lenalidomide

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, o Clinical Trial using auranofin

University of Kansas - Recruiting 18 years or older.
- A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL).
auranofin

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemi Clinical Trial using PCI 32765

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion.
PCI 32765

B-Cell Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocyto Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Idelalisib; Rituximab

Gilead Sciences - Recruiting 65 years or older.
- A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Idelalisib; Rituximab

CLL, or Leukemia Clinical Trial using Eltrombopag

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia.
Eltrombopag

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Autologous tumor cell extract vaccine

Xeme Biopharma Inc. - Recruiting 18 years or older.
- A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia.
Autologous tumor cell extract vaccine

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

University of Wisconsin, Madison - Recruiting 18 years or older.
- HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxanr) and Lenalidomide (Revlimidr) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

Leukemia Clinical Trial using Cyclophosphamide; Rituximab; Sapacitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH.
Cyclophosphamide; Rituximab; Sapacitabine

B Cell Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using CD19CAR-28-zeta T cells; Ipilimumab

Baylor College of Medicine - Recruiting N/A or older.
- Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia.
CD19CAR-28-zeta T cells; Ipilimumab

Leukemia Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT).
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cance Clinical Trial using carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).
carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Leukemia, or Lymphoma Clinical Trial using anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL).
anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

Grupo Espanol de trasplantes hematopoyeticos y terapia celular - Recruiting 18 years to 70 years.
- Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC.
Ofatumumab

Chronic Lymphocytic Leukemia Clinical Trial using Valproic acid

All India Institute of Medical Sciences, New Delhi - Recruiting 18 years or older.
- Use of Valproic Acid in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Valproic acid

Leukemia Clinical Trial using Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy

Cambridge Antibody Technology - Recruiting 18 years or older.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL).
Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy